FDA action counts
| Total FDA actions | 1 |
|---|---|
| Warning letters | 1 |
| Recalls | 0 |
| Approval records | 0 |
| Form 483 inspection citations | 0 |
| Most recent action | June 8, 2026 |
Enforcement history
On 2026-06-08, Argus HQ recorded an FDA Warning Letter for Nova Vascular LLC dba NOVARX, rated "critical" severity in Argus HQ's classification: Nova Vascular LLC dba NOVARX — False & Misleading Claims/Misbranded (Telehealth) (2026-06-08). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. Nova Vascular LLC dba NOVARX has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Frequently asked questions
- What is the most recent FDA action on file for Nova Vascular LLC dba NOVARX?
- June 8, 2026. Argus HQ ingests new FDA enforcement records daily.
- Has Nova Vascular LLC dba NOVARX received FDA warning letters?
- Yes, 1 warning letter on file. See the full history below for each one.
- Is this FDA enforcement data for Nova Vascular LLC dba NOVARX official?
- Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
- How many FDA actions has Nova Vascular LLC dba NOVARX had?
- Argus HQ has recorded 1 FDA events for Nova Vascular LLC dba NOVARX: 1 warning letters, 0 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Enforcement History: Nova Vascular LLC dba NOVARX. Digital Empire LLC. Retrieved from https://argushq.ai/company/nova-vascular-llc-dba-novarx
"FDA Enforcement History: Nova Vascular LLC dba NOVARX." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/nova-vascular-llc-dba-novarx.
Argus HQ Research. "FDA Enforcement History: Nova Vascular LLC dba NOVARX." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/nova-vascular-llc-dba-novarx.
@misc{argushq_argushq_ai_company_nova_vascular_llc_dba_novarx_2026,
title = {FDA Enforcement History: Nova Vascular LLC dba NOVARX},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/company/nova-vascular-llc-dba-novarx},
note = {Accessed: July 13, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗